ATE346070T1 - Purinderivate als kinaseinhibitoren - Google Patents

Purinderivate als kinaseinhibitoren

Info

Publication number
ATE346070T1
ATE346070T1 AT03711146T AT03711146T ATE346070T1 AT E346070 T1 ATE346070 T1 AT E346070T1 AT 03711146 T AT03711146 T AT 03711146T AT 03711146 T AT03711146 T AT 03711146T AT E346070 T1 ATE346070 T1 AT E346070T1
Authority
AT
Austria
Prior art keywords
kinase inhibitors
purine derivatives
purine
derivatives
formula
Prior art date
Application number
AT03711146T
Other languages
German (de)
English (en)
Inventor
Joshua Ryan Clayton
Clive Gideon Diefenbacher
Thomas Albert Engler
Kelly Wayne Furness
James Robert Henry
Sushant Malhotra
Angela Lynn Marquart
Johnathan Alexander Mclean
David Mendel
Timothy Paul Burkholder
Yihong Li
Jon Kevin Reel
John Morris Sullivan
Brian Raymond Berridge
Charles Edward Ruegg
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE346070T1 publication Critical patent/ATE346070T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
AT03711146T 2002-03-05 2003-03-04 Purinderivate als kinaseinhibitoren ATE346070T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36224502P 2002-03-05 2002-03-05

Publications (1)

Publication Number Publication Date
ATE346070T1 true ATE346070T1 (de) 2006-12-15

Family

ID=27805149

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03711146T ATE346070T1 (de) 2002-03-05 2003-03-04 Purinderivate als kinaseinhibitoren

Country Status (16)

Country Link
US (4) US7491716B2 (https=)
EP (1) EP1483265B1 (https=)
JP (1) JP4414232B2 (https=)
KR (1) KR100974770B1 (https=)
CN (1) CN1312154C (https=)
AT (1) ATE346070T1 (https=)
AU (1) AU2003215325B8 (https=)
BR (1) BR0308243B1 (https=)
CA (1) CA2477967C (https=)
CY (1) CY1109006T1 (https=)
DE (1) DE60309848T2 (https=)
DK (1) DK1483265T3 (https=)
ES (1) ES2276048T3 (https=)
IL (2) IL163781A0 (https=)
PT (1) PT1483265E (https=)
WO (1) WO2003076442A1 (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04008671A (es) * 2002-03-08 2004-12-06 Lilly Co Eli Derivados de pirrol-2,5-diona y su uso como inhibidores de gsk-3.
GB0212049D0 (en) * 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
ATE486872T1 (de) 2005-02-09 2010-11-15 Arqule Inc Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
US20080207594A1 (en) * 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
WO2006117221A1 (en) * 2005-05-04 2006-11-09 Develogen Aktiengesellschaft Use of azapaullones for preventing and treating pancreatic autoimmune disorders
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007225088B2 (en) * 2006-03-13 2012-09-13 Kyorin Pharmaceutical Co., Ltd Aminoquinolones as GSK-3 inhibitors
EP1845098A1 (en) 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN101302216B (zh) * 2007-05-11 2011-08-10 上海睿智化学研究有限公司 稠环吲哚类化合物的制备方法
AU2008268613A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Quinazolinone compounds and methods of use thereof
EP2392574B1 (en) 2007-06-22 2013-12-18 ArQule, Inc. Indolyl pyrrolidines for the treatment of cancer
WO2009002806A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PL2315756T3 (pl) * 2008-07-08 2015-02-27 Incyte Holdings Corp 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA2758473C (en) 2009-04-14 2013-12-17 Eli Lilly And Company Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
PH12012500778A1 (en) 2009-10-30 2012-11-26 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
WO2011082266A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted heterocyclic compounds
WO2011089416A1 (en) 2010-01-19 2011-07-28 Astrazeneca Ab Pyrazine derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP5984837B2 (ja) * 2010-12-23 2016-09-06 アークル インコーポレイテッド ピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにそれを調製および使用する方法
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
HK1206250A1 (en) 2012-06-26 2016-01-08 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and ped 10 inhibitors for use in the treatment of neurological or metabolic disorders
WO2014009305A1 (en) 2012-07-09 2014-01-16 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
WO2014098000A1 (en) * 2012-12-17 2014-06-26 Daiichi Sankyo Company, Limited Process for preparation of a tricyclic heterocycle
TW201506010A (zh) 2013-06-26 2015-02-16 Daiichi Sankyo Co Ltd 三環雜環化合物之製造方法
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
US11066419B2 (en) * 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
AU2018250591A1 (en) 2017-04-11 2019-10-10 Frequency Therapeutics, Inc. Methods for hair follicle stem cell proliferation
WO2019126686A1 (en) * 2017-12-21 2019-06-27 Frequency Therapeutics, Inc. 1,2-dihydro-3h-pyrazol-3-one compounds and methods of using same
US10526343B2 (en) 2018-03-26 2020-01-07 University Of Sharjah Heterocyclic systems and pharmaceutical applications thereof
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
KR102919209B1 (ko) 2018-08-10 2026-01-28 다이아핀 테라퓨틱스, 엘엘씨 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료
US20200121681A1 (en) 2018-10-17 2020-04-23 Frequency Therapeutics, Inc. Methods for hair follicle stem cell proliferation
WO2020132045A1 (en) 2018-12-19 2020-06-25 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN112390794B (zh) * 2019-08-19 2023-05-26 鲁南制药集团股份有限公司 一种米诺膦酸关键中间体的制备方法
CN115925622B (zh) * 2023-02-10 2025-04-22 山西永津集团有限公司 一种3-氰基吡啶-2-基氨基甲酸叔丁酯的合成方法
CN115974850B (zh) * 2023-02-16 2024-08-06 中国药科大学 一类作为akr1c3抑制剂的化合物及其制备方法与用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ280738B6 (cs) 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
WO2001044247A2 (en) 1999-12-16 2001-06-21 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
ES2220585T3 (es) 1999-12-16 2004-12-16 Eli Lilly And Company Agentes y procedimiento para el tratamiento de enfermedades proliferativas.
YU4403A (sh) 2000-07-27 2006-05-25 F. Hoffmann-La Roche Ag. Derivati 3-indolil-4-fenil-1h-pirol-2,5-diona, kao inhibitori glikogen sintaza kinaze-3 beta
IL156339A0 (en) 2000-12-08 2004-01-04 Ortho Mcneil Pharm Inc Indazolyl-substituted pyrroline compounds as kinase inhibitors
JP2004526676A (ja) 2000-12-08 2004-09-02 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド キナーゼ阻害剤として有用な大員複素環式化合物

Also Published As

Publication number Publication date
AU2003215325A1 (en) 2003-09-22
EP1483265A1 (en) 2004-12-08
US20090105229A1 (en) 2009-04-23
KR20040087338A (ko) 2004-10-13
AU2003215325B2 (en) 2008-09-18
AU2003215325B8 (en) 2008-10-09
KR100974770B1 (ko) 2010-08-06
US7491716B2 (en) 2009-02-17
DK1483265T3 (da) 2007-03-19
IL163781A0 (en) 2005-12-18
ES2276048T3 (es) 2007-06-16
US20110207721A1 (en) 2011-08-25
CY1109006T1 (el) 2014-07-02
BR0308243A (pt) 2005-01-11
US8022065B2 (en) 2011-09-20
PT1483265E (pt) 2007-01-31
IL163781A (en) 2010-04-15
JP4414232B2 (ja) 2010-02-10
DE60309848D1 (de) 2007-01-04
WO2003076442A1 (en) 2003-09-18
JP2005526072A (ja) 2005-09-02
EP1483265B1 (en) 2006-11-22
CN1312154C (zh) 2007-04-25
CA2477967C (en) 2010-08-10
US8058425B2 (en) 2011-11-15
BR0308243B1 (pt) 2014-08-26
DE60309848T2 (de) 2007-05-16
CA2477967A1 (en) 2003-09-18
US20050090483A1 (en) 2005-04-28
US20110294792A1 (en) 2011-12-01
CN1639165A (zh) 2005-07-13

Similar Documents

Publication Publication Date Title
ATE346070T1 (de) Purinderivate als kinaseinhibitoren
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
DK1761520T3 (da) Kinaseinhibitorer
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
IL163777A0 (en) Kinase inhibitors
BR0313330A (pt) Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE552834T1 (de) Zubereitung von 1,6-disubstituierten azabenzimidazolen als kinasehemmer
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
CY1110933T1 (el) 5,7-διαμινοπυραζολο[4,3-d]πυριμιδινες με ανασταλτικη της pde-5 δραστικοτητα
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
CY1110064T1 (el) Παραγωγα φαινυλ-πιπεραζινης ως αναστολεις επαναπροσληψης σεροτονινης
DE60321808D1 (de) Flavon derivate als inhibitoren von cyclin-abhängigen kinasen
CY1109234T1 (el) Αναστολεις κινασης
EA201200891A1 (ru) Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина
ATE355265T1 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
ATE438398T1 (de) Pyrrolo-dihydroisochinolin-derivate als pde10- inhibitoren
DE60316984D1 (de) Benzoylsulfonamide als antitumor-mittel
EA200600607A1 (ru) Производные имидазопиридина в качестве ингибиторов индуцируемой no-синтазы
EA200801200A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
EA200600601A1 (ru) Производные аминопиридина в качестве ингибиторов индуцируемой no-синтазы
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1483265

Country of ref document: EP